The evanescence and persistence of RBC alloantibodies in blood donors
Ronald G. Hauser, Denise Esserman, Matthew S. Karafin, Sylvia Tan, Raisa Balbuena‐Merle, Bryan R. Spencer, Nareg H. Roubinian, Yanyun Wu, Darrell J. Triulzi, Steve Kleinman, Jerome L. Gottschall, Jeanne E. Hendrickson, Christopher A. Tormey, (for the NHLBI Recipient Epidemiology and Donor Evaluation Study‐III (REDS‐III))
Abstract
BACKGROUND Blood donors represent a healthy population, whose red blood cell (RBC) alloantibody persistence or evanescence kinetics may differ from those of immunocompromised patients. A better understanding of the biologic factors impacting antibody persistence is warranted, as the presence of alloantibodies may impact donor health and the fate of the donated blood product. METHODS Donor/donation data collected from four US blood centers from 2012 to 2016 as part of the Recipient Epidemiology and Donor Evaluation Study‐III (REDS‐III) were analyzed. Clinically significant antibodies from blood donors with more than one donation who underwent at least one follow‐up antibody screen after the initial antibody identification were included. Of 632,378 blood donors, 481 (128 males and 353 females) fit inclusion criteria. RESULTS Antibody screens detected 562 alloantibodies, with 368 of 562 (65%) of antibodies being persistently detected and with 194 of 562 (35%) becoming evanescent. Factors associated with antibody persistence included antibody specificity, detection at the first donation, reported history of transfusion, and detection of multiple antibodies concurrently. Anti‐D, C, and Fy a were most likely to persist, while anti‐M, Jk a , and S were most frequently evanescent. CONCLUSIONS These data provide insight into variables impacting the duration of antibody detection, and they may also influence blood donor center policies regarding donor recruitment/acceptance.